Jun NH2-Terminal Kinase Phosphorylation of p53 on Thr-81 Is Important for p53 Stabilization and Transcriptional Activities in Response to Stress by Ivanov, Vladimir N. et al.
MOLECULAR AND CELLULAR BIOLOGY,
0270-7306/01/$04.0010 DOI: 10.1128/MCB.21.8.2743–2754.2001
Apr. 2001, p. 2743–2754 Vol. 21, No. 8
Copyright © 2001, American Society for Microbiology. All Rights Reserved.
Jun NH2-Terminal Kinase Phosphorylation of p53 on Thr-81 Is
Important for p53 Stabilization and Transcriptional Activities in
Response to Stress
THOMAS BUSCHMANN,1 OLGA POTAPOVA,2 ANAT BAR-SHIRA,3 VLADIMIR N. IVANOV,1
SERGE Y. FUCHS,1† SCOTT HENDERSON,4 VICTOR A. FRIED,5 TOSHINARI MINAMOTO,6
DANIA ALARCON-VARGAS,1 MATTHEW R. PINCUS,7 WILLIAM A. GAARDE,8 NIKKI J. HOLBROOK,2
YOSEF SHILOH,3 AND ZE’EV RONAI1*
The Ruttenberg Cancer Center1 and Department of Cell Biology,4 Mount Sinai School of Medicine, New York,
Department of Cell Biology and Anatomy, New York Medical College, Valhalla,5 and Department of Pathology and
Laboratory Medicine, State University of New York Health Science Center, Brooklyn,7 New York; Cell Stress and Aging
Section, Laboratory of Biological Chemistry, National Institute on Aging, National Institutes of Health, Baltimore,
Maryland2; Department of Human Genetics and Molecular Medicine, Sackler School of Medicine, Tel Aviv University,
Tel Aviv, Israel3; Cancer Research Institute, Kanazawa University, Kanazawa, Japan6; and Isis Pharmaceuticals Inc.,
Carlsbad, California8
Received 9 October 2000/Returned for modification 28 November 2000/Accepted 24 January 2001
The p53 tumor suppressor protein plays a key role in the regulation of stress-mediated growth arrest and
apoptosis. Stress-induced phosphorylation of p53 tightly regulates its stability and transcriptional activities.
Mass spectrometry analysis of p53 phosphorylated in 293T cells by active Jun NH2-terminal kinase (JNK)
identified T81 as the JNK phosphorylation site. JNK phosphorylated p53 at T81 in response to DNA damage
and stress-inducing agents, as determined by phospho-specific antibodies to T81. Unlike wild-type p53, in
response to JNK stimuli p53 mutated on T81 (T81A) did not exhibit increased expression or concomitant
activation of transcriptional activity, growth inhibition, and apoptosis. Forced expression of MKP5, a JNK
phosphatase, in JNK kinase-expressing cells decreased T81 phosphorylation while reducing p53 transcrip-
tional activity and p53-mediated apoptosis. Similarly transfection of antisense JNK 1 and -2 decreased T81
phosphorylation in response to UV irradiation. More than 180 human tumors have been reported to contain
p53 with mutations within the region that encompasses T81 and the JNK binding site (amino acids 81 to 116).
Our studies identify an additional mechanism for the regulation of p53 stability and functional activities in
response to stress.
The TP53 gene encodes a short-lived transcription factor
implicated in the regulation of cell cycle progression, DNA
repair, replicative senescence, and programmed cell death (21,
43, 47). The p53 protein is normally expressed at low levels in
nonstressed normal growing cells. In response to DNA damage
or stress, p53 is modified posttranslationally, with resultant
accumulation of transcriptionally active protein (21, 43, 47).
Activation of p53 in response to stress leads to temporary
growth arrest or apoptosis. Mutations in p53, which are com-
mon in human tumors, abrogate its ability to contribute either
to growth arrest or to cell death (43, 60). Most mutations found
within the DNA-binding domain of p53 impair its binding to
target DNA sequences (58). Different p53-responsive genes
mediate a variety of cellular functions, including growth arrest
by p21WAF1/CIP1 and 14-3-3 (12, 28) and apoptosis by Bax,
CD95/Fas, IGF-BP3, and p53-inducible genes (6, 39, 44, 45).
However, the mechanisms that enable activation of a selective
subset of p53 target genes are poorly understood.
Accumulating evidence suggests that the regulation of p53’s
transcriptional activities depends on the nature of its phos-
phorylation (3, 16, 21, 37). Furthermore, a key factor that
determines p53’s ability to mediate its multiple activities is its
stability, which is tightly regulated by Mdm2 and Jun NH2-
terminal kinase (JNK) in a phosphorylation-dependent man-
ner (8, 17, 18, 21, 25, 34). In nonstressed cells, Mdm2 targeting
of p53 ubiquitination primarily occurs in the G2/M phase of the
cell cycle, whereas JNK association and targeting of p53 for
ubiquitination take place during the G0 phase (17). In response
to stress, p53 phosphorylation coincides with its dissociation
from both Mdm2 and JNK (17, 51).
More than a dozen phosphorylation sites have been mapped
on p53, but only a few have been characterized with respect to
the phosphorylating kinase and the relevance of the phosphor-
ylation to p53 activities. Within the C terminus, human p53 is
phosphorylated at amino acids 315, 378, 389, and 392, which
enhances the in vitro specific DNA-binding activity of p53 (30,
31, 36, 54). At the p53 N terminus, several potential phosphor-
ylation sites have been identified, including Ser 6, 9, 15, 20, 33,
37, and 46 and Thr 18 and 55 (11, 20, 21, 32, 37). ATM (ataxia
telangiectasia mutated) has been implicated in Ser 15 phos-
phorylation (4, 40, 51, 53), which is induced by DNA damage
(40, 53) and which is associated with enhanced p53 transcrip-
tional activities (11, 49, 51). Gamma irradiation-induced ATM-
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dependent activation of Chk2 results in phosphorylation of Ser
20, which has been implicated in p53 transcriptional activities
(10, 29), p53 tetramerization, down-regulation of Mdm2 sup-
pression, p53 stabilization in response to stress (10, 57, 51, 52),
and p53-mediated apoptosis (52, 59).
Phosphorylation by p38 kinase on Ser 33 and 46 has been
shown to be required for UV-induced p53-mediated apoptosis
(7), and inhibition of p38 has been found to attenuate tran-
scriptional activities of p53 and p53-dependent apoptosis in-
duced by chemotherapeutic agents (50). Phosphorylation-
driven acetylation of p53 on C-terminus sites activates
sequence-specific DNA binding (24, 49) and has also been
implicated in transcription-dependent p53-mediated apoptosis
(9).
Together, these observations point to a complex array of
phosphorylation events occurring in response to stress and
DNA damage that involve multiple kinases and multiple phos-
phoacceptor sites. The regulation of such complex phosphor-
ylation patterns may involve sequential phosphorylation
events, as was shown for phosphorylation of Ser 15, which
depends on phosphorylation at Ser 46 (7).
In earlier studies we established the contribution of JNK to
the regulation of p53 stability. In cells in the G0 and G1 phases
of the cell cycle, among other specific conditions, JNK but not
Mdm2 is associated with p53 and JNK efficiently targets the
ubiquitination and degradation of p53; similarly, JNK serves as
a targeting molecule for ubiquitination of nonphosphorylated
c-Jun (15), ATF2 (19), and JunB (14). The JNK association
with p53 has been mapped to residues 97 to 116 (2), whose
deletion prolongs p53’s half-life (17). Expression of constitu-
tively active JNK kinase (JNKK) upstream kinase MEKK1
increases p53 stability and transcriptional activity (18). Given
the multiple downstream effectors of MEKK1, we further elu-
cidated the possible contribution of JNK to p53’s stability and
activities. Here we identify and characterize T81 as the phos-
phoacceptor site for JNK phosphorylation. We show that phos-
phorylation of T81 in response to stress or DNA damage
stabilizes p53 and confers on it transcriptional activities and
the ability to elicit apoptosis. In the absence of JNK expression
or JNK-mediated phosphorylation, p53 is inactive. The impli-
cations of JNK phosphorylation at T81 for p53 activities in the
context of the complex phosphorylation of p53 in response to
stress are discussed.
MATERIALS AND METHODS
Cells. 293T (ATCC CRL1573) human embryo kidney cells, early passages of
normal human fibroblasts (NHF; kind gift from H. Tahara), MCF7 breast cancer
cells (ATCC HTB22), and p53 null cells (human lung tumor H1299 and mouse
fibroblast 10.1 cell lines; kindly provided by X. Wu, and S. Aaronson, respec-
tively) were grown in Dulbecco modified Eagle medium supplemented with
antibiotics and 10% fetal bovine serum.
Oligonucleotide synthesis and treatment. The oligonucleotides used were
synthesized at Isis Pharmaceuticals, Inc. The sequences of the oligonucleotides
are as follows: JNK1AS (ISIS12439), 59-CTC TCT GTA GGC CCG CTT GG-39;
JNK2AS (ISIS18076), 59-GTC CGG GCC AGG CCA AAG TC-39; JNK1Scr
(ISIS101759), 59-CTT TCC GTT GGA CCC CTG GG-39; JNK2Scr
(ISIS101769), 59-GTG CGC GCG AGC CCG AAA TC-39. All oligonucleotides
consisted of 29-O-methoxyethyl modified sugars (residues 1 to 5 and 16 to 20) and
2-deoxy sugars (residues 6 to 15). The linkages are uniform phosphorothioate.
Cells were treated with 0.25 mM oligonucleotides in the presence of 10 mg of
Lipofectin reagent (Life Technologies)/ml as described previously (46).
Expression vectors. Human p53 cDNA was used as a backbone for generating
a PCR-based site-directed single-base-pair substitution at amino acid (aa) 81
(Quick Change; Stratagene), generating p53T81A, which was confirmed by se-
quencing. Rat p53 mutated at aa 101, 105, and 108 or with aa 97 to 116 deleted
(DP7) and the constitutively active forms of JNKK2 and MEKK1 kinases have
been previously described (18). FLAG-tagged MKP5 expression vector was con-
structed by amplifying the MKP5 open reading frame using reverse transcription-
PCR and subcloning the amplification product into a pcDNA3.0 plasmid (In-
vitrogen). A monoclonal antibody directed against MKP5 was raised against a
fragment spanning aa 2 to 154 of MKP5 (A. Bar Shira et al., unpublished data).
In vitro phosphorylation of p53 by purified JNK. 293T cells (108) were calcium
transfected with hemagglutinin (HA)-tagged JNK2 (30 mg) and 36 h later treated
with UV-C (40 J/m2). Proteins prepared within 45 to 60 min after irradiation
were subjected to immunoprecipitation using antibodies to HA. Immunoblotting
and silver staining were performed on an aliquot of the purified material to
ensure an appropriate degree of purity. Activity of HA-JNK was verified using
glutathione S-transferase (GST)–Jun as a substrate in solid-phase kinase reac-
tions. Wild-type (wt) or T81A mutant forms of p53 were in vitro translated using
an in vitro translation kit (TNT; Promega). The translated proteins were purified
using p53 antibodies (pAb 421) that were covalently bound to Amino link beads
(Pierce). Bound p53 was eluted from the antibodies using elution buffer (Pierce)
followed by dialysis against kinase buffer (20 mM HEPES [pH 7.6], 1 mM
EGTA, 1 mM dithiothreitol, 2 mM MgCl2, 2 mM MnCl2, 5 mM NaF, 1 mM
NaVO3, 50 mM NaCl). The amount and purity of p53 were verified by silver
staining and immunoblotting before equal aliquots were subjected to an in vitro
solid-phase kinase reaction (1). Briefly, bead-bound HA-JNK was incubated with
p53 at 37°C for 15 min in the presence of [g-32P]ATP (50 cpm/fmol) in the
presence of kinase buffer. The reaction mixture was then separated by sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and subjected
to Coomassie blue staining to confirm equal loading of p53. The gel was dried,
and phosphorylation of p53 was determined by autoradiography. In all cases the
buffers used contained a cocktail of protease and phosphatase inhibitors (1).
Stress and DNA damage treatments. UV irradiation was administered as
previously described (1). Briefly, cells were subjected to UV-C irradiation (254
nm; 40 J/m2) in the calibrated area within the tissue culture hood. Medium that
had been removed prior to irradiation was returned to minimize serum-induced
changes. Treatment with anisomycin (10 mg/ml), hydrogen peroxide (100 mM),
sorbitol (0.6 mM), or cis-platinum (0.6 mM) (all purchased from Sigma) was
performed by adding them to the medium (time zero) followed by time point
analysis as indicated in Results.
Protein stability analysis. To monitor changes in the stability of p53, pulse-
chase analysis was performed using the previously described [35S]methionine-
cysteine mixture (17). Briefly, 10.1 p53 null cells (106) were transfected with the
wt or T81A mutant form of p53 (2 mg) using Lipofectamine Plus reagent
(GIBCO-BRL). Twenty-four hours after transfection the cells were starved (se-
rum without methionine) for 1 h before addition of [35S]methionine-cysteine
mixture (1 mCi) to cells for 1 h (time zero followed by chase for the periods of
time indicated by the time points in the pertinent figures. Cells were counted and
harvested, followed by protein preparation and p53 immunoprecipitation from
equal numbers of cells (using 2 mg of DO1 antibodies per 106 cells). Cyclohex-
imide-chase experiments were performed on cells transfected as indicated above,
and 24 h later cycloheximide (60 mg/ml) was added to the cultures (time zero).
Equal amounts (500 mg) of proteins prepared at various time points were sub-
jected to immunoprecipitation (DO1) followed by immunoblot analysis (poly-
clonal p53 antibody).
Mass spectrophotometry analysis. 293T cells (108) were transfected (calcium
phosphate) with p53 and JNKK2CAA expression vectors. Twenty-four hours after
transfection, protein extracts were incubated with p53 antibodies (DO1) immo-
bilized on Aminolink beads (Pierce). Immunoprecipitates were eluted from
antibodies reduced and alkylated with iodoacetamide before SDS-PAGE (22). A
portion of the gel was electroblotted, followed by immunoblotting to reveal the
position of p53. Coomassie blue-stained protein bands were excised from SDS-
PAGE gels and digested with trypsin in situ (48). The digests containing the gel
bits were extracted in 50% acetonitrile–0.1% trifluoroacetic acid (TFA), concen-
trated using a SpeedVac to less than 10 ml, and desalted using a Zip-Tip (Mil-
lipore, Bedford, Mass.). An aliquot of the digest was mixed with an equal volume
of matrix material (a-cyano-4-hydroxy-cinnamic acid) (Sigma) as a saturated
solution in 50% acetonitrile–0.05% TFA, and ion masses were determined by
matrix-assisted laser desorption–time of flight mass spectroscopy (42) (Kratos;
KOMPACT MALDI III). The instrument was calibrated over the range 905.05
to 5,734.59 atomic mass units using peptide mass standards (PerSeptive Biosys-
tems).
Immunoblot analysis. Polyclonal antibodies to phosphorylated T81 (boldface)
were generated (Research Genetics) in rabbits against phosphopeptide PAPAA
PTPAAPAP. Serum was precleared on a nonphosphorylated peptide followed by
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affinity purification on the phosphorylated peptide. Immunoblot analysis with
phospho-T81 antibody was performed (using a dilution of 1/100) on proteins that
were prenormalized with respect to total p53 levels followed by enhanced chemi-
luminescence detection (Amersham). In all other cases Western blotting was
performed using equal amounts of proteins. Immunoprecipitations were carried
out on 1-mg quantities of cellular extracts using the relevant antibodies and
protein G beads (GIBCO-BRL).
Confocal immunofluorescence. Cells grown on 22-mm2 coverslips were fixed in
freshly prepared 2.5% para-formaldehyde in phosphate-buffered saline (PBS)
(pH 7.4) for 10 min at room temperature. The cells were then washed three times
(5 min each) in PBS followed by permeabilization in 0.1% Triton X-100 in PBS
(pH 7.4) for 5 min and an additional three 5-min washes in PBS. The cells were
incubated on 75-ml drops of anti-p53 antibodies (FL-393; Santa Cruz Biotech-
nology) diluted (200 ng/ml) in PBS (pH 7.4) containing 1% bovine serum albu-
min (BSA) for 1 h at room temperature in a humidity chamber. The cells were
washed three times in PBS (5 min each) before incubation with 75-ml drops of
fluorescein-conjugated anti-rabbit immunoglobulin G (Vector Laboratories) di-
luted (15 mg/ml) in PBS (pH 7.4) containing 1% BSA for 1 h at room temper-
ature in a humidity chamber in the dark. The cells were washed three times in
PBS (5 min each), followed by a brief wash in 0.1% Triton X-100 in PBS, pH 7.4
(5 min), and three additional 5-min washes in PBS, and the coverslips were
mounted on glass slides in Vectashield (Vector Laboratories).
Transcriptional activation and growth inhibition assays. The Mdm2 and
p21CIP1/WAF1 minimal promoter-driven luciferase constructs (cotransfected with
b-galactosidase [b-Gal] expression vector) were analyzed 24 h after transfection
as previously described (18). Growth inhibition assays were performed in six-well
plates using H1299 cells transfected with wt or mutant p53T81A. Cells (triplicate
wells) were subjected to G418 selection for 3 weeks before clones were stained
and counted.
Apoptosis and cell cycle studies. p53 null cells were exposed to treatments 24 h
after transfection. Apoptosis was assessed by annexin-V–fluorescein isothiocya-
nate staining in the presence of propidium iodide (PI) (Pharmingen). Cell cycle
analysis of green fluorescent protein (GFP)-positive cells was carried out using
fluorescence-activated cell sorter analysis of PI-stained cells (5 3 104 cells per
sample) using a Calibur flow cytometer (Becton Dickinson) under wide-scatter
gates. The data were analyzed using CellQuest software.
RESULTS
Mass spectrometry analysis of p53 phosphorylation by JNK.
Human p53HA immunopurified from JNKK
CAA-expressing
293T cells was separated by SDS-PAGE and digested in situ
with trypsin. Analysis of the peptide digests by mass spectrom-
etry identified a peptide mass (m/z) of 3528.5 from the p53/
JNKK1 isolate that was not detectable in the p53/JNKK2
digest. Conversely, a peptide mass (m/z) of 3446.2 was found in
the digest of the p53/JNKK2 sample but was not detected in
the p53/JNKK1 digest. A theoretical tryptic digest of p53 pre-
dicts a unique m/z of 3445.97 corresponding to peptide 66 to
101. Within the 0.1% error of the mass spectrometer, our
results are consistent with a single phosphorylation of p53
peptide 66 to 101 (3445.97 1 80 5 3525.97) caused by coex-
pression of p53 with JNKKCAA. Subsequent analysis was car-
ried out on T81, which is the only residue within this region
that is a proline-directed Ser/Thr, a conserved JNK phos-
phoacceptor site. Analogs of human proline-driven T81 are
found in p53 from other species, including mice (Thr 78), rats
(Thr 89), and canines (Thr 76).
T81 is phosphorylated by JNK. Immunopurified JNK phos-
phorylated the wt p53 but not the mutant form of p53 in which
T81 was replaced with Ala (T81A) (Fig. 1a). To detect T81
phosphorylation in vivo, we raised antibodies to a phosphory-
lated T81 peptide. Recognition by phospho-T81 antibodies was
inhibited by a phosphorylated, but not by a nonphosphory-
lated, peptide corresponding to this domain (Fig. 1b). Coex-
pression of the constitutively active forms of MEKK1
(DMEKK1) or JNKK (JNKK2CAA), but not MKK6
(MKK6DD), with wt p53 led to efficient phosphorylation of wt
p53 detected by phospho-T81 antibodies. Neither kinase could
phosphorylate the p53 T81A mutant (Fig. 1c). These data
suggest that JNK, but not p38, phosphorylates p53 at T81. In
the same vein, forced expression of JNK2APF, a dominant-
negative form of JNK decreased MEKK1- as well as JNKK-
mediated phosphorylation of p53 on T81 (Fig. 1c). Expression
of a 20-aa peptide that corresponds to the JNK association site
on p53 (P7) and that disrupts the JNK-p53 complex in vivo and
in vitro (16) decreased JNKK-dependent phosphorylation of
p53 on T81 (not shown). Similarly, JNKK did not induce phos-
phorylation of T81 on p53 whose JNK docking site had been
deleted or mutated (18), indicating that the association of JNK
with p53 is required for its phosphorylation at T81 (Fig. 1d).
These experiments establish that JNK phosphorylates p53 on
T81.
T81 is phosphorylated in vivo following exposure to DNA-
damaging agents. To determine changes in T81 phosphoryla-
tion in response to stress and DNA damage, NHF were ex-
posed to heat shock, cis-platinum, anisomycin, H2O2, or UV
treatment. Immunoblot analysis using antibodies to phospho-
T81 revealed that T81 is phosphorylated in vivo within 1 h after
exposure to heat shock, hydrogen peroxide, sorbitol, or UV
(Fig. 2a; please note that the level of p53 has been normalized
to ensure that changes in phosphorylation are not due to al-
tered expression level). The degree of JNK activation in re-
sponse to these treatments was monitored via immunokinase
reactions using GST-Jun as a substrate (Fig. 2b). Treatment
with cis-platinum (Fig. 2a) or X rays (not shown) neither ac-
tivated JNK nor phosphorylated p53 at T81 in the NHF cells.
Time course analysis demonstrated that the degree of T81
phosphorylation depends on the UV dose. Low-dose UV irra-
diation (10 J/m2), which causes growth arrest, resulted in T81
phosphorylation within as little as 30 min (not shown), with
increased phosphorylation after 1 to 2 h. The level of T81
phosphorylation remained above background even 24 h after
UV treatment (Fig. 2a). In response to high-dose irradiation
(50 J/m2), which causes apoptosis, phosphorylation on T81 was
seen within 1 h, peaked within 4 h, and declined to background
levels within 24 h (Fig. 2a). The kinetics of T81 phosphoryla-
tion was consistent with increased levels of p53 in response to
these stress-inducing agents (1, 17).
Substitution of T81 for Ala attenuates UV- and JNK-medi-
ated p53 stabilization. A prerequisite for p53 ability to elicit its
activities is its enhanced stability, which is phosphorylation
dependent (18). The association of nonactive JNK with p53,
which takes place under nonstressed conditions, targets p53
ubiquitination and degradation in an Mdm2-independent man-
ner (17). Conversely, signaling by upstream JNKK kinase
MEKK1 prolongs p53’s half-life (16). To monitor the half-life
of p53 mutated on T81A, p53 null cells were transfected with
the wt or T81A mutant forms of p53 and pulse-chase analysis
was carried out under normal growth conditions as well as after
UV irradiation or JNKK expression.
Both wt and T81A forms of p53 exhibited short half-lives in
the absence of stress (Fig. 3, left). This finding indicates that
both forms are similarly targeted for ubiquitination and deg-
radation. In response to UV treatment the half-life of wt p53
was prolonged, compared with the half-life of the T81A mu-
tant (Fig. 3, middle). These data suggest that mutation in T81
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is sufficient to impair the stabilization of p53 in response to UV
irradiation. To directly address whether JNK’s ability to alter
p53 stability is impaired in the T81A mutant, p53 null (10.1)
cells were cotransfected with the constitutively active form of
JNKK2 (JNK2CAA) and either the wt or the T81A form of p53.
Half-life measurements performed on the cells 24 h later re-
vealed that JNKK increased the stability of the wt but not the
T81A form of p53 (Fig. 3, right). Differences in the half-life of
the T81A form of p53 in response to JNKK were more notice-
able than those after UV treatment. This is not surprising in
light of the multiple kinases induced by UV treatment, which
contribute to p53 phosphorylation and stabilization, including
p38 and Chks (7, 10, 21, 40, 51, 52). These observations suggest
that T81 phosphorylation is required for JNK-mediated
changes in p53 stability. Further support for the role of JNK in
stabilizing p53 via T81 was obtained from analysis of p53 sta-
bility under cycloheximide-chase conditions (27). Exposure of
cells to cycloheximide conditions (60 mg/ml) that activate JNK
but block protein synthesis revealed a prolonged half-life for
the wt, but not the T81A, form of the protein (data not shown).
These data establish the role of T81 in p53 stabilization fol-
lowing UV irradiation or JNK activation.
Role of T81 phosphorylation in p53 transcriptional activi-
ties, p53-mediated growth inhibition, and growth arrest. To
determine whether T81 phosphorylation is important for acti-
vation of p53’s biological functions, we first assessed the trans-
activation capacities of the T81A mutant. Basal transcriptional
activities of p21WAF1/CIP1 promoter sequences linked to a lu-
ciferase reporter were fivefold higher for wt p53 than for the
T81A form, which exhibited activities similar to those seen
FIG. 1. JNK phosphorylates p53 on T81. (a) Wild-type or mutant (T81A) forms of human p53 were in vitro translated, purified, and subjected
to phosphorylation using JNK immunopurified from UV-treated 293T cells. Middle, immunoblot analysis of material subjected to autoradiography
using DO1 antibodies. The doublet represents the nonphosphorylated (lower band) and phosphorylated (upper band) forms of p53. The control
reaction using c-Jun as a substrate (immunokinase [IK] reaction of GST-Jun) and the level of HA-JNK2 that was immunoprecipitated (IP-HA-
JNK2) are shown (bottom). (b) Proteins prepared from NHF that were exposed to sham stress (control) or heat shock (HS; 42°C for 1 h) were
subjected to immunoblot analysis using the antibodies to phosphorylated T81 in the presence of excess phospho or nonphospho peptides as
indicated (top) or to Western blotting using DO1 antibodies (bottom). (c) T81 phosphorylation on wt or T81A forms of p53 was monitored after
cotransfection of the respective construct (1 mg) with the indicated upstream kinases (3 mg) into H1299 cells. Analysis of T81 phosphorylation was
carried out using the antibodies to phospho-T81. Bottom, p53 levels detected with DO1 antibodies. (d) T81 phosphorylation of p53 impaired in
JNK association. Either wt rat p53 or p53 with deletions (DP7) or mutations (at aa 101, 105, and 108) within the region, which encompasses the
JNK binding site (1, 18) was cotransfected with JNK2CAA into H1299 cells. Proteins were prepared and subjected to Western blot analysis using
phospho-T81 antibodies (top) or DO1 antibodies (bottom).
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with the empty expression vector. A substantial increase (16-
fold over basal levels) in the level of p21WAF1/CIP1-mediated
luciferase activity upon expression of the constitutively active
form of MEKK1 (DMEKK1) was recorded. In response to the
constitutively active JNKK2 (JNKK2CAA) or after UV irradi-
ation, the expression of the wt but not the T81A form led to a
sixfold increase in transcriptional activities mediated by
p21WAF1/CIP1 (Fig. 4a) or Mdm2 promoter sequences (data not
shown). Transcriptional activities of T81A were equal to those
of transcriptionally “dead” hot spot p53 mutants (at aa 248 and
273), before as well as after UV irradiation (Fig. 4b). Corre-
sponding to the level of luciferase activity driven by the
p21WAF1/CIP1 promoter are expression levels of p21WAF1/CIP1,
which were monitored via Western blotting (Fig. 4b, bottom).
These data suggest that phosphorylation on T81 contributes to
transcriptional activities of p53 in response to stress.
As p53-dependent transcription of p21WAF1/CIP1 is required
for p53-dependent growth arrest in response to stress (21, 43,
47), we next assessed the fraction of 10.1 cells expressing wt or
T81A p53 in the G1 phase of the cell cycle upon treatment with
Taxol or nocodazole, which were selected to represent the
agents known to affect the cell cycle and cell death in a p53-
dependent manner (56). Whereas, following exposure to Taxol
or nocodazole, 42 and 49% of wt p53-expressing cells, respec-
tively, accumulated in the G1 phase, only 21 and 10% of T81A-
expressing cells, respectively, exhibited a G1 arrest (Fig. 4c).
The decrease in the fraction of cells found in G1 upon expres-
sion of T81A coincided with an elevated fraction of cells within
the G2/M phase of the cell cycle, which is characteristic of
transcriptionally inactive mutant forms of p53 (66 versus 47%
after Taxol treatment and 68 versus 39% after nocodazole
treatment; Fig. 4c). Further analysis was carried out to inves-
tigate the growth-inhibitory properties of T81A mutant p53.
Forced expression of wt or T81A forms in H1299 cells followed
by G418 selection revealed that wt p53 expression resulted in
33 6 6.5 colonies, compared with 82 6 7.7 colonies upon
FIG. 2. In vivo phosphorylation of T81 in response to stress and
DNA damage. (a) NHF cells were subjected to the indicated treat-
ments (heat shock [HS], 42°C for 1 h; UV-C (254 nm), 10 or 50 J/m2
[UV]; H2O2 [HP], 100 mM; cis-platinum [CP], 0.6 mM; sorbitol [S], 0.6
M), and proteins were prepared 1 h later unless indicated otherwise.
The quantities of p53 used for the Western blotting were prenormal-
ized to assure equal loading of p53 and thus do not reflect changes in
the amount of p53 seen after these treatments. Upper lane, analysis
with antibodies to phospho-T81; lower lane, analysis with DO1 anti-
bodies to p53. (b) JNK activity in the protein samples analyzed in panel
a, upper lane (1-h time point), was monitored via the solid-phase
kinase reaction using GST-Jun1–87 as a substrate.
FIG. 3. Stability of p53 mutated at T81. Pulse-chase analysis of p53 half-life was performed as indicated in Materials and Methods using 10.1
p53 null cells that had been transfected with either wt or T81A forms of p53. At the indicated time points, p53 was immunoprecipitated with DO1
antibodies followed by autoradiography. The half-lives of p53 under nonstressed conditions and in response to UV irradiation or following JNK
activation (forced expression of JNKK2CAA) are shown. Bottom, corresponding densitometry analysis, which was carried out in three independent
experiments.
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FIG. 4. Activity of p53 mutated at T81. (a) p53 null cells were transfected with p21WAF1/CIP1-Luc, a constitutively active form of MEKK1 or
JNKK2 and wt or mutant forms of p53. (Inset) Expression levels of the p53 forms in extracts used for transcriptional analysis. Basal transcriptional
activities of wt p53 were five times higher than those seen with either the T81A mutant or empty vector. The data shown reflect fold increases over
basal activity of the construct. C, control; M, DMEKK1; J, JNKKCAA. (b) Comparison of T81A transcriptional activities with those of different
transcriptionally dead p53 mutants. Mouse 10.1 p53 null cells were transfected with p21WAF1/CIP1-Luc and wt or mutant forms of p53. Cells were
treated with UV (15 J/m2) 36 h later, and proteins were prepared after an additional 6 h. Analysis was carried out as indicated in panel a. Bottom,
Western blots of proteins prepared from the same experiment using antibodies to p53 and p21WAF1/CIP. (c) p53 vectors and GFP were transfected
into 10.1 cells, and 24 h later cells were treated with Taxol or nocodazole (5 mg/ml). PI staining and flow cytometry analyses of GFP1 cells were
performed 16 h after treatment as detailed in Materials and Methods. (d) H1299 cells were transfected with the constructs and 24 h later were
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expression of the T81A mutant and 85 6 9.3 colonies in cells
transfected with the empty vector. These data point to the
requirement of T81 phosphorylation as a prerequisite of p53-
dependent cell growth inhibition. In agreement with earlier
observations that identified aa 65 to 90 as essential for p53 to
mediate growth arrest (61), our findings pinpoint the require-
ment for the single amino acid T81.
Forced expression of wt or T81A forms of p53 in H1299 cells
increased the fraction of apoptotic cells, suggesting that T81A
p53 is as potent as the wt p53 protein in eliciting this basal
degree of apoptosis (Fig. 4d). However, in response to aniso-
mycin or UV irradiation, wt p53 caused a significantly greater
extent of cell death than mutant T81A p53 (Fig. 4d). These
data suggest that T81 phosphorylation contributes to p53’s
ability to mediate apoptosis in response to stress and DNA
damage. The basal degree of cell death elicited by the T81A
form of p53 may be attributed to the ability of p53 to elicit
apoptosis even when it is transcriptionally inactive (26).
Forced expression of a peptide (P7) which corresponds to
the JNK docking site efficiently blocked JNK association with,
and phosphorylation of, p53, whereas it did not affect other
JNK substrates (not shown). The ability of p53 to mediate
programmed cell death in response to UV irradiation was
impaired (15 to 5% after 24 h and 57 to 21% after 72 h) upon
expression of P7, but not control peptide C7 (Fig. 4e). These
findings further support the role of JNK in regulating the
ability of p53 to elicit UV-induced cell death.
JNK phosphatase MKP5 efficiently attenuates JNK-medi-
ated T81 phosphorylation, p53 transcriptional activities, and
p53-mediated apoptosis. As an independent approach to in-
vestigating the role of JNK in T81 phosphorylation and in p53
activities, we used specific JNK/p38 phosphatase MKP5 (55).
Forced expression of MKP5 in JNKK-expressing cells reduced
the level of T81 phosphorylation in a dose-dependent manner
(Fig. 5a). MKP5 expression decreased, albeit less efficiently,
T81 phosphorylation in response to UV irradiation (Fig. 5a).
Under these conditions, MKP5 did not affect the level of Ser 15
phosphorylation. Differences in MKP5 effects on T81 phos-
phorylation in JNKK versus UV-treated cells may be attrib-
uted to the degree of MKP5 activities. Analysis of JNK phos-
phorylation revealed that MKP5 was less effective in removing
phospho groups from JNK in UV-treated cells than in JNKK-
expressing ones. Accordingly, UV may attenuate MKP5 activ-
ities, which would also explain why MKP5 was less effective in
attenuating T81 phosphorylation in UV-treated cells. Further
support for the role of JNK in T81 phosphorylation and activ-
ities comes from comparison between wt and T81A mutant
forms of p53. Coexpression of JNKK and p53 (wt or T81A) in
p53 null mouse fibroblasts in the presence or absence of MKP5
revealed a clear increase in T81 phosphorylation on the wt but
not the T81A mutant form of p53, which was attenuated upon
MKP5 expression. Decreased T81 phosphorylation coincided
with a decrease in p21 expression (Fig. 5b). These results co-
incide with luciferase assays performed under the same condi-
tions. Expression of JNKK with p53 in p53 null cells caused a
threefold increase in p53 transcriptional activities, monitored
using Bax and p21 promoter sequences linked to the luciferase
reporter gene. However, addition of MKP5 to the transfection
mixture decreased p53 transcriptional activities. The degree of
decreased p53 transcription depended on the amount of MKP5
transfected (Fig. 5c). MKP5 did not have any effect on Mdm2-
luc or Bax-luc activities (data not shown). These observations
further support the role of JNK in T81 phosphorylation and
transcriptional activities.
To further assess the effect of JNK on p53 activities, we
monitored the degree of apoptosis in JNKK-transfected cells.
Forced expression of p53 in p53 null fibroblasts was sufficient
to induce a low level of apoptosis, and cotransfection of p53
and JNKK led to a substantial increase, from 13 to 30%, in the
basal degree of apoptosis (Fig. 5d). These results are in accor-
dance with the changes to apoptosis in response to MEKK1
treatment (18). Whereas UV treatment led to a threefold (15
to 45%) increase in the degree of apoptosis, a higher level of
apoptosis (58%) was seen in the presence of JNKK (Fig. 5d).
Coexpression of MKP5 with JNKK efficiently decreased the
basal level of apoptosis (from 30 to 18%, where 13% is the
basal level) and, to a lesser extent, the degree of UV-induced
apoptosis (from 58 to 50%; Fig. 5d). These findings suggest
that JNK efficiently increases p53’s ability to elicit apoptosis. In
response to UV irradiation, it is the combination of other
UV-inducible kinases that contributes, in concert with a UV-
mediated decrease in MKP5 activities, to the limited effect of
MKP5 on UV-induced apoptosis, compared with the effect on
JNKK-expressing cells. Importantly, p53 mutated on T81 was
not able to elicit apoptosis in response to JNKK expression,
nor was it affected upon MKP5 expression (Fig. 5d). These
results further confirm the requirement of T81 phosphoryla-
tion for p53’s ability to elicit programmed cell death in re-
sponse to JNK stimuli.
Cellular localization of wt and T81 p53 following JNKK and
MKP5 expression. Given the relationship between cellular lo-
calization of p53 and its stability and activities, we monitored
possible changes in p53 distribution after JNKK and MKP5
expression. As shown in Fig. 6, the expression of either JNK
kinase or its phosphatase did not alter the nuclear localization
of p53. These data suggest that JNK phosphorylation does not
affect the cellular compartmentalization of p53. A similar anal-
ysis performed on the T81A form of p53 revealed that the lack
of the JNK phosphorylation site led to equal distribution of
this p53 mutant in the cytoplasm and the nucleus, which was
not affected by MKP5 or by JNKK expression (Fig. 6, bottom).
Cellular distribution of either wt or T81A forms of p53 was not
affected by UV irradiation, nor was it changed upon leptomy-
cin B treatment (not shown). Since the phosphoacceptor site
studied here lies within the proline-rich domain, which has
been implicated in p53 conformation, we also monitored pos-
treated with anisomycin (10 mg/ml) or UV-C irradiation (15 J/m2). Analysis of cell death was performed after an additional 36 h. The fraction of
dead cells shown includes annexin-V- and PI-positive cells, thereby including apoptotic and necrotic death. (e) 3T3 mouse fibroblasts were
transfected with P7 (corresponding to the JNK binding site on p53) or C7 (P7 sequence in scrambled order) cloned into pcDNA3HA. UV
irradiation was administered 24 h later. The degree of apoptosis was calculated 24 or 72 h after irradiation based on fluorescence-activated cell
sorter analysis of PI-positive cells. The inset depicts immunocytochemistry analysis of P7 expression.
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sible changes of p53 conformation due to its mutation on T81.
Unlike p53 mutated on aa 248 (13), T81A p53 retained the
conformation of wt p53 forms, as determined on the basis of
the peptide digest pattern (data not shown).
T81 phosphorylation is attenuated in cells treated with an-
tisense JNK. To further establish the role of JNK in the phos-
phorylation of T81, we used antisense oligonucleotides to both
JNK1 and JNK2 (JNK1AS and JNK2AS). Previous studies
established that treatment of cells with JNK-AS efficiently
blocks JNK expression at the RNA and protein levels (46),
thereby creating a transient nearly null environment for JNK.
Using MCF7 cells (which contain the wt form of p53), we
FIG. 5. JNK phosphatase attenuates T81 phosphorylation and p53 activities. (a) p53 null cells were transfected with p53, a constitutively active
form of JNKK, and different concentrations of MKP5. Cells were exposed to 45 J of UV-C/m2, as indicated. Top, specific phosphorylation pattern
of T81. Phosphorylation on serine 15 after UV treatment and the expression of p53 are shown. Controls revealing the expression of exogenously
transfected MKP5-phosphorylated and nonphosphorylated forms of JNK1 and -2 are also shown. (b) p53 null cells were transfected with wt or
T81A mutant forms of p53 together with JNKKCAA and MKP5 as indicated. Analysis for expression of p53 and p53 phosphorylation on T81 and
a control analysis for p21WAF1/CIP1 expression and JNK phosphorylation (and nonphosphorylation) levels were carried out 36 h after transfection.
(c) p53 null cells were transfected with either p21-luc or Bax-luc constructs, together with the indicated vectors and b-Gal. For transfection
efficiency lysates were normalized with respect to b-Gal activity and subjected to a luciferase assay. The diagram reflects changes in luciferase
activity in six independent transfections. (d) 10.1 cells were transfected with the indicated constructs together with GFP, and 24 h after transfection
cells were treated with 45 J of UV-C PI staining and flow cytometry analysis of GFP1 cells were performed 16 h after UV treatment. The diagram
shows changes in apoptotic cell death after six independent transfections.
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monitored changes in endogenous p53 phosphorylation on T81
following UV irradiation of cells pretreated with JNK1AS and
JNK2AS. Transfection of JNK1AS and JNK2AS led to a sig-
nificant decrease in the level of JNK1 and JNK2 RNA (not
shown) and in protein levels (Fig. 7). Within 2 h after UV
irradiation, T81 was similarly phosphorylated in mock-,
pcDNA3-, and control antisense-oligonucleotide-transfected
cells. However, a substantially lower degree of phosphorylation
was evident in the JNK1AS- and JNK2AS-transfected cells
(Fig. 7). These results establish that in vivo phosphorylation of
T81 in response to UV treatment is mediated by JNK.
T81 and the JNK docking site on p53 are often mutated in
human cancer. A further indication of the importance of JNK
phosphorylation on T81 for p53 functions comes from the
finding that human tumors contain p53 with mutations within
the JNK binding and phosphorylation sites. A search of the p53
mutant database for mutations within T81 identified two cases
of breast and skin tumors with p53 mutated at this site. More
than 180 additional tumors were found to harbor p53 with
mutations on residues within, or adjacent to, the JNK docking/
phosphorylation sites (aa 81 to 117), indicating that mutations
occur frequently in this area (5). This finding provides addi-
tional evidence of the importance of JNK association and
phosphorylation of p53.
DISCUSSION
Increasing evidence points to the physiological importance
of posttranslational modifications for p53 stability and activi-
ties. Those modifications include phosphorylation and sumoy-
lation, which have been associated with the transcriptionally
active form of p53 (21, 23, 37). Whereas p53 modification by
FIG. 6. Cellular localization of wt and T81A p53 forms. p53 null 10.1 cells were transfected with wt p53, p53 plus JNKKCAA, p53 plus JNKKCAA
plus MKP5, p53T81A, p53T81A plus JNKKCAA, or p53T81A plus JNKKCAA plus MKP5. Cells were immunolabeled with a rabbit polyclonal antibody
to p53 (FL-393) (Santa Cruz Biotechnology) (diluted 1:500) followed by detection with fluorescein-conjugated anti-rabbit immunoglobulin G
(heavy plus light chains) (Vector Laboratories). Cells were illuminated with the 488-nm line of the argon laser of a Leica TCS-SP (UV) confocal
laser scanning microscope and examined using a 1003, 1.4 -numerical-aperture objective lens. For wt p53 (top three panels), labeling is restricted
primarily to the nucleus (excluding the nucleoli) and nuclear bodies. Little or no cytoplasmic labeling is seen. For p53T81A (bottom three panels),
labeling is divided between the nucleus and the cytoplasm. The lower left panel shows a pair of cells that are completing division. In the lower right
panel, p53T81A is divided evenly between the nucleus and the cytoplasm in cells that express the protein at higher levels; at lower expression levels,
it is found primarily in the nucleus. In all cases, p53 labeling is restricted from the nucleolus. Bars, 10 nm
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conjugation to SUMO-1 on a single lysine residue (K386) is
thought to enhance the transactivation activity of p53, multiple
phosphorylation sites appear to be required for p53 stability
and transcriptional activities.
The present study examines the role of in vivo phosphory-
lation of the newly recognized T81 site in response to various
stress stimuli and shows that JNK is the phosphorylating ki-
nase. Support for T81 as the JNK phosphoacceptor site has
been provided by seven independent approaches, including (i)
in vivo phosphorylation of p53 by JNKK as revealed by mass-
spectrometric analysis of immunopurified p53, (ii) in vitro
phosphorylation of bacterially expressed p53 by a purified form
of active JNK, (iii) lack of phosphorylation by p38, (iv) inhibi-
tion of T81 phosphorylation by the dominant-negative form of
JNK, (v) lack of T81 phosphorylation on p53 that lacks the
JNK binding site, (vi) inhibition of JNK phosphorylation in
vivo in cells that exhibit the nearly null JNK environment
generated by JNK antisense oligonucleotides, and (vii) inhibi-
tion of T81 phosphorylation in vivo by JNK phosphatase
MKP5.
Phosphorylation at this site is of crucial importance in rela-
tion to p53’s ability to elicit transcriptional activation under
conditions where JNK is activated (i.e., UV) and was abolished
in p53 mutated at T81. Abrogated transactivation of p53 im-
paired its ability to elicit growth arrest, growth inhibition, and
programmed cell death, all of which are key regulatory events
in p53-mediated responses of cells to DNA damage. A lower
degree of nuclear accumulation, as revealed by our confocally
based immunohistochemistry analysis, may account for some,
but not all, of the observed decrease in T81A p53’s ability to
elicit transcriptional activities of p21, Mdm2, or Bax. Whereas
50% of the T81A form of p53 is localized within the nucleus,
90% of p53 transcriptional activities were lost. Furthermore,
T81A p53’s loss of function also cannot be attributed to altered
conformation, since peptide digestion revealed a pattern sim-
ilar to that of the wt but not that of the conformationally
altered 248 mutant. Lack of a significant difference in the
half-life of p53 under nonstressed conditions also supports the
notion that the T81A protein is under regulation similar to that
of the wt counterpart.
Independent confirmation of the role of JNK phosphoryla-
tion of T81 on p53 was provided by the use of JNK1 and -2
antisense oligonucleotides and JNK phosphatase MKP5. Ex-
pression of antisense JNK1 and -2 efficiently attenuated UV-
mediated T81 phosphorylation in cells. Along those lines,
forced expression of MKP5 effectively reduced T81 phosphor-
ylation following JNKK expression. A less-pronounced effect
was seen in UV-treated cells, probably as result of the activa-
tion of additional p53 kinases that also contribute to p53 sta-
bility as well as to the attenuation of MKP5’s activities. MKP5
was also efficient in attenuating both JNKK-mediated p53 tran-
scriptional activity and JNKK-dependent p53-elicited apopto-
sis. Taken together, our data provide direct support for the
finding that JNK phosphorylation of p53 takes place at T81
and that this phosphorylation is important for p53 stability and
activities.
It is important to note that p53 phosphorylation by JNK is
conformation sensitive; attempts to phosphorylate in vitro the
GST-p53 fusion protein with JNK failed unless the GST por-
tion of the protein was first removed (2). In this connection it
is notable that an earlier study suggested that JNK phosphor-
ylates p53, but at a residue different from that reported in the
present study (38). This discrepancy may also relate to the use
of murine p53; the site in question (Ser 34) has no human
counterpart.
It is necessary to understand the relationship between phos-
phorylation on T81 and that on other sites that are phosphor-
ylated in response to DNA damage, including Ser 15, 20, 33,
46, and 389. Growing evidence suggests that the type and dose
of stress or damage incurred are important factors in deter-
mining the type of kinases induced and the pattern of p53
phosphorylation (8). It is likely that phosphorylation on certain
residues may precede that on others. Accordingly, phosphor-
ylation at one site may be required to acquire a certain con-
formation, enabling subsequent phosphorylation events to take
place on other domains of p53. Such a model is supported by
the finding that Ser 15 phosphorylation is affected by mutation
of Ser 33 and Ser 46, which are p38 phosphorylation sites (7),
which may explain the different kinetics that are often ob-
served in an examination of p53 phosphorylation on different
residues. Along these lines, although phosphorylation of p53
by JNK at T81 is important for p53 transactivation, it is likely
to be augmented by other stress- and DNA damage-responsive
kinases (e.g., ATM, p38, Chk2) that phosphorylate p53 on
other residues. The requirement for coordinated phosphoryla-
tion of p53 by different kinases implies that JNK phosphory-
lation on T81 may not be sufficient for p53 stabilization and
transcriptional activities, thereby explaining why certain JNK
activators (e.g., interleukin 1) do not stabilize or activate p53
(41). Lack of JNK phosphorylation under such conditions may
FIG. 7. JNK antisense oligonucleotides attenuate T81 phosphory-
lation in vivo. MCF7 cells were transfected with either specific anti-
sense oligonucleotides directed against JNK1 and JNK2 or nonspecific
antisense oligonucleotides (250 nM each). Forty-eight hours after
transfection, cells were either sham treated or UV treated and har-
vested 2 h after treatment. Top, specific T81 phosphorylation; middle,
expression level of p53 in response to indicated treatments; bottom,
expression of JNK1 and -2 in the presence or absence of transfected
oligonucleotides. Control lane, no treatment; mock lipofection, cells
maintained in concentrations of Lipofectin equal to those for the
oligonucleotide-transfected samples; JNK1AS and JNK2AS, JNK an-
tisense oligonucleotides that were transfected; JNKScr, control
“scrambled” oligonucleotides.
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be overruled by other stress-inducible kinases that can phos-
phorylate p53 on other residues.
An important indication of the importance of T81 in p53
functions comes from the observation that close to 200 human
tumors contain p53 with mutations within the domain that
encompasses JNK binding and JNK phosphorylation sites.
Those mutants are expected to exhibit impaired JNK associa-
tion and phosphorylation and, as a result, to lack transcrip-
tional activities.
In establishing the role of JNK and T81 in the stability and
activity of p53, our study identifies an additional mechanism
underlying the p53-dependent cellular response to stress and
damage.
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